Articles by Daniel Marsh
Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran
Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.
Tesla Stock Stalls Despite Retail Buying Surge as Valuation Hits 300x Earnings
Tesla shares remained nearly unchanged despite a tripling of retail purchases to $372 million, as valuation concerns persist with the stock trading at over 300 times earnings.
S&P 500 Options Sentiment Hits 4-Year Bullish Peak as Rally Loses Steam
S&P 500 call-to-put ratio hits 0.9, a four-year high, even as index slips. JPMorgan raises target to 8,000, but limited upside remains.
Lilly's Foundayo Wins UK Approval, Lifting Shares Nearly 3%
Eli Lilly's (LLY) shares jumped 2.9% after the UK became the first European country to approve its oral weight-loss drug Foundayo, adding about $30 billion to its market value.
Costco's July Sales Rise 10.7%, But Valuation Concerns Cap Stock Gains
Costco's July sales climbed 10.7% to $23.12B, but shares were flat as the market weighs a rich 47.7x P/E against steady comps of 6.6%. Analysts' $1,090 target implies a 48x forward multiple.
Apple Drops $97B After Jefferies Downgrade on iPhone Concerns
Apple (AAPL) lost about $97 billion in market value after Jefferies downgraded the stock to Underperform, citing iPhone pricing and margin pressures.
Archer Aviation Soars 11% on Boeing Deal, Eyes $200M Revenue
Archer Aviation (ACHR) jumped 11% after agreeing to acquire Boeing's Insitu, Wisk, and SkyGrid, adding $200M in annual revenue and a strategic partnership.
Sionna Therapeutics Collapses 92% After Phase 2a Setback
Sionna Therapeutics (SION) tumbled 92% after its Phase 2a trial failed to meet the primary endpoint, pushing the market cap below its cash holdings. Vertex (VRTX) rose on reduced competitive risk.
Global Stocks Outperform US in 2026, Trading at 32% Valuation Discount
VXUS outperforms VTI in 2026 with a 15.99% return vs 14.59%, while trading at a 32% lower P/E. Global diversification adds minimal cost.